Pinned Tweet
So excited to be heading to @wiscurology for residency!
Special thanks to @JoshMeeks @rebrannigan @JoshuaHalpernMD for their incredible mentorship along the way.
On Wisconsin!
#AUAmatch
Special thanks to @JoshMeeks @rebrannigan @JoshuaHalpernMD for their incredible mentorship along the way.
On Wisconsin!
#AUAmatch
9
5
72
Arighno Das retweeted
🔬 Patterns of Lymph Node Metastases in Ureteral Cancer
This study maps lymph node metastasis (LNM) patterns in mid and distal ureteral tumors to refine surgical templates, crucial for cancer staging and treatment.
🔎 Largest to Date - Analyzes 45 LNMs in 24 patients
🦠 ound in 53% of mid and 39% of distal tumors
📈 Implications - Supports retroperitoneal LND in clinical practice
#Urology #CancerResearch #LymphNodeMapping #UTUC
tnyp.me/cEjLsI4I/x
This study maps lymph node metastasis (LNM) patterns in mid and distal ureteral tumors to refine surgical templates, crucial for cancer staging and treatment.
🔎 Largest to Date - Analyzes 45 LNMs in 24 patients
🦠 ound in 53% of mid and 39% of distal tumors
📈 Implications - Supports retroperitoneal LND in clinical practice
#Urology #CancerResearch #LymphNodeMapping #UTUC
tnyp.me/cEjLsI4I/x
3
5
15
2,384
Arighno Das retweeted
📣 Latest Article Online!
🩺 Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis by Sagar R. Patel et al
🔎 Link to Article: buff.ly/wK5emk0
✨ We thank all the le contribution!
@SagarRPatelMD
@UroDocAsh
@AmandaMyersMD
@UrogerliMD
@JoshMeeks
@UroDhino
@SWilliams_MD
@AndreaNecchi
@nnavai
@LAUrology_NL
@paolo_gontero
@Agarwal_CaB
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@DaveDandrea
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
🩺 Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis by Sagar R. Patel et al
🔎 Link to Article: buff.ly/wK5emk0
✨ We thank all the le contribution!
@SagarRPatelMD
@UroDocAsh
@AmandaMyersMD
@UrogerliMD
@JoshMeeks
@UroDhino
@SWilliams_MD
@AndreaNecchi
@nnavai
@LAUrology_NL
@paolo_gontero
@Agarwal_CaB
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@DaveDandrea
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
0
23
51
6,690
Arighno Das retweeted
The “golden age of grift” may be coming to medicine.
Prediction markets are now being introduced to clinical trials, creating opportunities for insider trading, conflicts of interest, and manipulation of trial outcomes.
My new paper in @JCO_ASCO @ASCO: doi.org/10.1200/JCO-26…
pubmed.ncbi.nlm.nih.gov/42874020/
@profgalloway @edels0n
Prediction markets are now being introduced to clinical trials, creating opportunities for insider trading, conflicts of interest, and manipulation of trial outcomes.
My new paper in @JCO_ASCO @ASCO: doi.org/10.1200/JCO-26…
pubmed.ncbi.nlm.nih.gov/42874020/
@profgalloway @edels0n
4
17
52
4,226
Arighno Das retweeted
6/ Stress urinary incontinence is a risk of surgery. Radiation more commonly causes urgency, irritative LUTS, cystitis, bowel toxicity, etc.
Which endpoints we emphasize matters. A comparison centered on pad use will predictably favor radiation; other toxicity measures tell a different part of the story.
My takeaways:
• PACE-A strengthens SBRT as an excellent option for low/intermediate-risk disease.
• Cancer control was similar between treatments.
• The toxicity profiles are different, not universally better or worse.
• These toxicity results should not automatically be extrapolated to higher-risk disease.
Important trial. Important results. No need to declare a winner.
Which endpoints we emphasize matters. A comparison centered on pad use will predictably favor radiation; other toxicity measures tell a different part of the story.
My takeaways:
• PACE-A strengthens SBRT as an excellent option for low/intermediate-risk disease.
• Cancer control was similar between treatments.
• The toxicity profiles are different, not universally better or worse.
• These toxicity results should not automatically be extrapolated to higher-risk disease.
Important trial. Important results. No need to declare a winner.
4
3
30
1,839
Arighno Das retweeted
YOUR 2026 CHICAGO WHITE SOX ARE HEADING TO THE POSTSEASON!
473
6,590
27,294
1,014,816
Of the many things I've learned during @SUO_YUO fellowship at @UTMDAnderson, learning how to apply clinical trial hazard ratios to obtain treatment effect (elegantly described here mdpi.com/2072-6694/14/1… by @PavlosMsaouel) may be one of the more important lessons! (1/)
Your patient has had nephrectomy for high-risk clear cell RCC. The next decision: Surveillance, Pembrolizumab, or Pembrolizumab + belzutifan. Is adjuvant justified when surgery may already have been curative? Our new commentary explores this dilemma. 🧵bit.ly/4jkism6
1
2
12
4,269
Using an anchored indirect approach and data from KN-564 and LS-022, we calculated an estimated HR of Pembrolizumab/Belzutifan vs. Surveillance.
Big picture: any truly informed discussion of adjuvant therapy in RCC needs a formal evaluation of baseline risk of recurrence (2/)
Big picture: any truly informed discussion of adjuvant therapy in RCC needs a formal evaluation of baseline risk of recurrence (2/)
1
2
1
578
Inclusion criteria for both trials are pretty heterogenous. Absolute risk reduction is small in trial-eligible patients at lower risk of recurrence. Has to be weighed against real risk of lifelong adverse events.
0
1
2
360
My daughter has never seen a Bears game where they’ve scored less than 50 points #DontGetTooUsedToIt
FINAL: The @ChicagoBears open the season with 59 points 😱
1
0
1
247
Arighno Das retweeted
1/5 New in @UrolOncol: consensus statements from the IKCS North America 2025 Think Tank on trials for rare kidney cancers. 46 experts. 20 statements. One message: move beyond pooled “non-clear cell” #kidneycancer primary analyses: authors.elsevier.com/a/1nmZc3r93nkV…
1
32
72
4,394
High fidelity model to simulate the modified Hautmann neobladder the @Uro_Rich way! @wiscurology @WiscUroRes
A Novel Ex Vivo Porcine Neobladder Simulation - Estelle C. Ndukwe, Frank C. Lin, Denise Mussehl, Anna Peacock, Kristin M. Ebert, Kyle A. Richards, 2026 journals.sagepub.com/doi/10.1177/21…
0
0
4
1,185
Arighno Das retweeted
It’s time to stop measuring inequities in cancer care and, instead, do something about it. Like the VA has for many years thanks to its spirit of leaving no one behind. va.gov/greater-los-an…
0
5
12
1,114
Arighno Das retweeted
1/5 Our study on panitumumab-based EGFR blockade in renal medullary carcinoma (RMC) is out in Clinical Cancer Research: aacrjournals.org/clincancerres/… #MsaouelLab, #endRMC #kidneycancer
13
50
109
11,228
Arighno Das retweeted
A really thought-provoking study at #ASCO26 (Abstr 4512, Clinical Science Symposium): decision regret after adjuvant pembrolizumab in RCC.
🔹 The question
Do patients regret receiving adjuvant pembro — and if so, is it driven by long-term toxicity that CTCAE grading doesn't y built a patient co-designed tool focused on long-term toxicity.
🔹 The study
104 RCC pts post-adjuvant pembro across 3 London centres, median f/u 30 mo. Pts completed the Ottawa Decision Regret Scale alongside their own rating of irAEs as life-changing, significant, or non-significant.
🔹 What they found
28% rated their toxicity as significant and 11% as life-changing — but these ratings did NOT correlate with CTCAE grade (a third of G1–2 events were rated significant), and regret was identical for G1–2 vs G3–4 irAEs. Regret was driven by patient-perceived long-term toxicity, especially permanent endocrine and MSK irAEs — and not by disease recurrence (only 1/14 who relapsed expressed regret). Lower baseline expectations of toxicity → more regret.
🔹 My take
Striking that >1 in 4 reported significant and >1 in 10 life-changing toxicity. What concerns me most isn't that CTCAE missed these events — it's that the grade didn't correlate with how significant patients found them, nor with regret at all. That deviates from the very purpose of grading. The hard part: a regret analysis is tough to contextualize when the alternative, no treatment, risks recurrence — arguably worse than a long-term toxicity. Adjuvant therapy is challenging by nature: most patients are either cured already or destined to recur regardless — we expose everyone to toxicity to benefit a minority. We urgently need biomarkers to find the few who truly benefit. This slide from @Prof_IanD says it all 👇
Looking forward to seeing the presentation!
🔗 asco.org/abstracts-pres…
#kcsm #ASCO26
@BethN01 @tompowles1
🔹 The question
Do patients regret receiving adjuvant pembro — and if so, is it driven by long-term toxicity that CTCAE grading doesn't y built a patient co-designed tool focused on long-term toxicity.
🔹 The study
104 RCC pts post-adjuvant pembro across 3 London centres, median f/u 30 mo. Pts completed the Ottawa Decision Regret Scale alongside their own rating of irAEs as life-changing, significant, or non-significant.
🔹 What they found
28% rated their toxicity as significant and 11% as life-changing — but these ratings did NOT correlate with CTCAE grade (a third of G1–2 events were rated significant), and regret was identical for G1–2 vs G3–4 irAEs. Regret was driven by patient-perceived long-term toxicity, especially permanent endocrine and MSK irAEs — and not by disease recurrence (only 1/14 who relapsed expressed regret). Lower baseline expectations of toxicity → more regret.
🔹 My take
Striking that >1 in 4 reported significant and >1 in 10 life-changing toxicity. What concerns me most isn't that CTCAE missed these events — it's that the grade didn't correlate with how significant patients found them, nor with regret at all. That deviates from the very purpose of grading. The hard part: a regret analysis is tough to contextualize when the alternative, no treatment, risks recurrence — arguably worse than a long-term toxicity. Adjuvant therapy is challenging by nature: most patients are either cured already or destined to recur regardless — we expose everyone to toxicity to benefit a minority. We urgently need biomarkers to find the few who truly benefit. This slide from @Prof_IanD says it all 👇
Looking forward to seeing the presentation!
🔗 asco.org/abstracts-pres…
#kcsm #ASCO26
@BethN01 @tompowles1
5
32
94
22,758
Arighno Das retweeted
🎆Editor's Choice!
📝"Current risk stratification for non-clear cell renal cell carcinoma (nccRCC) is largely derived from clear cell RCC (ccRCC) data. We evaluated recurrence patterns following surgery for nccRCC and compared the prognostic performances of various international lear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes by Arighno Das et al
🔎Read the full article on our website: buff.ly/Z1AHFP7
❗Disclaimer: The clinical relevance on this post was summarised for social media - refer to the full clarification on the article.
🙌We thank the authors for trusting EUO to publish your work!
@ArighnoD
@BCottaMD
@SurenaMatinMD
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
📝"Current risk stratification for non-clear cell renal cell carcinoma (nccRCC) is largely derived from clear cell RCC (ccRCC) data. We evaluated recurrence patterns following surgery for nccRCC and compared the prognostic performances of various international lear Cell: Rethinking Postoperative Surveillance for Non-clear Cell Renal Cell Carcinoma Subtypes by Arighno Das et al
🔎Read the full article on our website: buff.ly/Z1AHFP7
❗Disclaimer: The clinical relevance on this post was summarised for social media - refer to the full clarification on the article.
🙌We thank the authors for trusting EUO to publish your work!
@ArighnoD
@BCottaMD
@SurenaMatinMD
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect
2
9
14
1,544
Happy to see our GU @ASCO 2026 abstract highlighted by @KidneyCancer (kidneycancer.org/clinical-updat…)
nccRCC recurrence patterns are unique: often late (beyond 5y) and in the abdomen. Important data for optimizing post-operative surveillance. Just accepted into @EurUrolOncol
nccRCC recurrence patterns are unique: often late (beyond 5y) and in the abdomen. Important data for optimizing post-operative surveillance. Just accepted into @EurUrolOncol
0
0
4
156
